国产成人精品白浆久久69

“Federal marijuana scheduling merits reevaluation, but a wholesale transfer of marijuana to Schedule III fails to account for potency differences. Higher-potency marijuana is associated with a greater likelihood of adverse health reactions. 国产成人精品白浆久久69 has called for a more nuanced approach that limits down-scheduling to lower-potency marijuana and enforces Schedule III requirements for entities receiving any new tax benefits as a result. Such a targeted approach would open doors to new research opportunities while mitigating public health harms.”   

In 2024, 国产成人精品白浆久久69 provided comments to the Drug Enforcement Administration (DEA) on a proposed rule to reschedule marijuana to Schedule III.  

In the comment letter, 国产成人精品白浆久久69 recommended that the DEA consider the possible failure of marijuana with higher tetrahydrocannabinol (THC) concentrations to meet HHS’ new, alternative test for currently acceptable medical use. Further, significant, negative public health ramifications are likely to result if Internal Revenue Service Code Section 280E no longer applies, and thus marijuana companies/dispensaries were allowed to take advantage of various federal tax deductions and credits due to a transfer of marijuana to Schedule III. 

For these reasons, 国产成人精品白浆久久69’s letter noted that it could support a final rule that transfers only marijuana with lower THC concentrations to Schedule III, so long as any such final rule clearly states that (1) the Food, Drug, and Cosmetic Act (FDCA) will continue to apply, and (2) Schedule III requirements/controls will be enforced for those who take advantage of federal tax benefits due to 280E no longer being applicable after such a rescheduling. Higher potency marijuana would remain in Schedule I in the absence of Congressional action. 

国产成人精品白浆久久69’s Public Policy Statement on Cannabis is supportive of rescheduling cannabis used for medical purposes to promote more clinical research and Food and Drug Administration oversight typical of other medications.